5 recalls found for METOPROLOL SUCCINATE. Check if any of your products are affected.
Failed Dissolution Specifications
Teva Pharmaceuticals recalled 19,056 bottles of Metoprolol Succinate Extended-Release Tablets, 200 mg, sold nationwide. The recall cites failed dissolution specifications, which could affect how the drug releases in the body. Patients should stop using the product and contact Teva or their healthcare provider for guidance.
Teva Pharmaceuticals is recalling 18,780 bottles of Metoprolol Succinate Extended-Release Tablets, 25 mg, distributed nationwide. The recall is due to failed dissolution specifications that could affect dosing. Patients should stop using affected bottles and contact Teva or their healthcare provider for guidance.
Teva Pharmaceuticals recalled 67,043 bottles of Metoprolol Succinate Extended-Release Tablets, 50 mg, distributed nationwide. The FDA enforcement report cites Failed Dissolution Specifications as the hazard. Health care providers and patients should stop using this product immediately and contact Teva for guidance.
Teva Pharmaceuticals recalled 7,448 bottles of Metoprolol Succinate Extended-Release Tablets nationwide after failed dissolution specifications were identified. The recall involves 100 mg, 100‑tablet bottles (NDC 45963-677-11) and 1,000‑tablet bottles (NDC 45963-677-96). The defect may affect drug release and efficacy. Patients should stop using affected bottles and contact Teva or their clinician